LONGEVITY · Injectable
Thymalin.
Thymus peptide for immune and longevity
How it works
Class & mechanism.
In short
Thymalin is a thymus-derived peptide complex originally developed in Russian gerontology research. It is thought to work by helping restore T-cell balance and immune signalling that decline as the thymus gland shrinks with age. It is studied mainly for immune renewal and healthy-ageing support, with long-term human trial data suggesting associations with reduced age-related disease and mortality rates.
Class
Thymic Peptide Bioregulator Complex
Mechanism
Thymalin is a polypeptide complex of short-chain peptides (2–8 amino acids) extracted from the thymus glands of young calves, originally classified as a 'cytomedin' — a class of tissue-specific peptide bioregulators that regulate DNA transcription and cellular differentiation by penetrating target cell nuclei. It primarily acts on the thymus-immune axis: it restores T-lymphocyte differentiation and proliferation by binding thymocyte membrane receptors and activating intracellular signaling cascades, corrects the T/B lymphocyte ratio disrupted by aging-related thymic involution, enhances natural killer (NK) cell activity, normalizes cytokine balance, and stimulates hematopoiesis. At the gene expression level, Thymalin influences genes involved in cell proliferation, DNA repair, and apoptosis regulation, effectively reprogramming immune cells toward a younger functional phenotype.
Personalized Peptides provides DNA-driven peptide recommendations — we are not a compounding pharmacy, peptide synthesis company, or clinical provider.
Did you know
When Thymalin was combined with Epitalon and given annually for 6 consecutive years to elderly patients in the cited trial, all-cause mortality was reported to drop 4.1-fold — suggesting for every 4 deaths in the control group, roughly 1 occurred in the treated group. Few pharmaceutical interventions have reported a comparable figure in a human aging trial.
Preclinical Data
No human PK studies available.
Russian cytomedicine — no independent PK data
Class
Thymic bioregulator peptide complex (Khavinson)
Route
SC / IM
Mol. Weight
850 Da
What we don't know
No PK studies in Western literature. As a natural peptide extract (not a single synthetic peptide), PK characterisation is inherently complex. Metabolism presumably follows standard proteolytic degradation pathways.
Why this dosing protocol
Khavinson protocol: 5-10mg SC/IM daily for 10-30 days per course, 2-3 courses per year for immune ageing. The cyclical approach mirrors the broader Russian bioregulator philosophy — short, intensive tissue-normalisation courses rather than continuous therapy. Often combined with Epitalon in longevity protocols.
Empirical protocol: 5-10mg SC daily × 10-30 days, 2×/year
Safety notes
- Natural extract — composition variability
- Russian-only clinical data
Sources
Pharmacokinetic data shown for educational context. All parameters are inferred or empirically derived — no formal human PK studies exist for this compound. Individual response varies. Not a substitute for clinical dosing guidance.
Benefits
What it does.
Immune restoration and T-cell renewal — may help restore T-lymphocyte differentiation, normalize T/B cell ratios, and correct immunosenescence caused by thymic involution; the landmark clinical trial reported a 2.0–2.4-fold reduction in acute respiratory disease incidence
All-cause and cardiovascular mortality data — one of the few therapeutic peptides with human clinical data suggesting a 2.0–2.1-fold reduction in all-cause mortality and a notable cardiovascular mortality reduction in elderly patients
Reduced incidence of age-related conditions — clinical trial patients showed lower reported rates of ischemic heart disease, hypertension, osteoarthritis, and osteoporosis versus untreated controls over 6–8 years
Cytokine response modulation — adjunct Thymalin use in severe COVID-19 elderly patients was associated with suppressed hyperinflammatory gene expression signatures linked to cytokine storm pathology
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
What this does not mean
Thymalin is a research chemical. The information on this page is educational and does not constitute medical advice, diagnosis, or treatment. Thymalin is not FDA-approved for treating immunosenescence, age-related disease, or any other use. This page does not recommend, endorse, or prescribe any compound for human use. Always consult a qualified healthcare provider before making health decisions. Personalized Peptides provides DNA-driven educational context and test interpretation — not clinical protocols or pharmaceutical recommendations.
In the longest human clinical trial ever conducted on a therapeutic peptide, 266 elderly patients (age 60+) followed for 6–8 years at two independent Russian and Ukrainian gerontological institutes showed 2.0–2.1-fold mortality reduction with Thymalin alone; combined annual Thymalin + Epithalamin treatment for 6 years achieved a 4.1-fold mortality reduction vs controls
SOURCE · Khavinson VK & Morozov VG, Neuroendocrinology Letters 24(3-4), 2003; Khavinson et al., PubMed PMID 12577695, 2002
Thymalin treatment in organotypic spleen tissue cultures increased tissue growth zone indices by 20–50%, stimulated lymphocyte proliferation, and reduced apoptosis by 29–42% — providing in vitro mechanistic evidence for its immunoregeneration effects
SOURCE · Anisimov VN & Khavinson VK, meta-analysis review 2010; PeptideInsight research summary
In the 266-patient trial, Thymalin-treated patients showed a 2.0–2.4-fold decrease in acute respiratory disease incidence, significant reduction in cardiovascular, endocrine, immune, and nervous system dysfunction markers, and normalized homeostasis and metabolism versus untreated controls
SOURCE · Khavinson VK & Morozov VG, Neuroendocrinology Letters 2003; full PDF available at khavinson.info
Adjunct Thymalin in elderly severe COVID-19 patients suppressed cytokine storm gene expression patterns and reduced the hyperinflammatory response associated with high mortality in this population — suggesting real-time immune modulation capability
SOURCE · Khavinson et al., COVID-19 adjunct therapy study, 2020; thymalin-peptide.com clinical data table
Protocol
How to use it.
Dosing
5–10 mg/day via intramuscular or subcutaneous injection for 5–10 consecutive days per course. Standard clinical protocol used in Russian trials: 10 mg/day × 10 days, 1–4 cycles per year depending on age, health status, and immune condition.
Cycle
1–4 cycles per year; most longevity protocols use 1–2 annual courses. The landmark 6-year trial used annual combined Thymalin + Epithalamin cycles for maximum mortality reduction. Short-course design (5–10 days) with long recovery intervals is characteristic of Khavinson bioregulator protocols.
Contraindications
When to skip it.
Well-established safety profile across 35+ years of clinical use in Russia (approved as pharmaceutical drug since the 1980s). Most common adverse reactions: localized injection site redness, transient fatigue. Derived from bovine thymus — contraindicated in documented bovine protein allergy. Not approved as pharmaceutical outside Russia; research use only in most other countries. Caution with autoimmune conditions due to immune activation effects.
Always cleared with your concierge before protocol start.
Regulatory Context
FDA compounding status.
| FDA Status | Risk Level | Compounding | Key Date |
|---|---|---|---|
| No specific FDA action | 🟢 Stable | Gray zone — no specific enforcement | No pending dates |
Thymus peptide for immune and longevity. Distinct from Thymosin Alpha-1 and Thymogen. Not on any FDA Category 1/2/3 lists. No pending PCAC review. Regulatory posture less defined than thymosin-family counterparts.
Source: FDA Federal Register, PCAC agendas, industry analyses. Educational context only — not legal advice. Review after July 23-24, 2026 PCAC meeting.
Pricing
What it costs.
Indicative range for Thymalin, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Includes vial and reconstitution guidance
- 03Concierge supplier match included with every protocol
See Thymalin pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $130–$194 USD